International medical cannabis platform company Akanda Corp. AKAN has signed a multi-year supply agreement with European medical cannabis company Cansativa GmbH to supply EU-GMP quality THC dried flower strains cultivated from its Portuguese operations at Holigen.
Under the agreement terms, Akanda will supply Cansativa Group with two EU-GMP quality strains of dried THC flower for distribution and sale to all pharmacies in Germany through the Cansativa platform. The contract specifies initial deliveries of a minimum of 1,000 kilograms over the first 12 months, with a right of first refusal to take on additional quantities that could result in the full capacity utilization of Holigen’s 2,000 kilograms per annum indoor production capacity. The initial shipment is anticipated to include up to 250 kilograms of each strain to be supplied no later than the fourth quarter of 2022.
“This supply agreement with Cansativa represents one of the largest supply agreements in the nascent European medical cannabis industry and is certainly Akanda’s most substantial commercial development to date,” stated Tej Virk, CEO of Akanda.
“Our EU GMP certified grow facility in Portugal has both the quality and scalability to meet the increasing demands for medical cannabis in fast-growing markets across the EMEA region, such as Germany. Once made available, our strains will rank among the highest THC level medical cannabis products available in the EU. We're looking forward to a long-term relationship with the Cansativa Group, a professional and collaborative partner who shares our mission to expand access to medical cannabis to improve the quality of lives. The fact that we executed this supply agreement only two months after Akanda closed the acquisition of Holigen shows tremendous partnership and hard work on both sides,” continued Virk.
Photo: Benzinga; Sources: courtesy of jarmoluk and lindsayfox via Pixabay
Related News
Akanda To Contest Unauthorized Liquidation Of Its Subsidiary, Bophelo Bio Science & Wellness
Akanda To Supply Tetra Bio-Pharma With Cannabis For FDA Trials Of Cancer-Pain Drug
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.